vs
Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Apollo Commercial Real Estate Finance, Inc. is the larger business by last-quarter revenue ($73.3M vs $57.3M, roughly 1.3× RHYTHM PHARMACEUTICALS, INC.). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs -83.0%, a 122.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 4.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -4.6%).
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ARI vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.3M | $57.3M |
| Net Profit | $29.2M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 39.7% | -82.2% |
| Net Margin | 39.9% | -83.0% |
| Revenue YoY | 4.0% | 36.9% |
| Net Profit YoY | -28.2% | -9.6% |
| EPS (diluted) | $0.19 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $73.3M | $57.3M | ||
| Q3 25 | $61.6M | $51.3M | ||
| Q2 25 | $70.9M | $48.5M | ||
| Q1 25 | $65.8M | $32.7M | ||
| Q4 24 | $70.5M | $41.8M | ||
| Q3 24 | $71.6M | $33.3M | ||
| Q2 24 | $81.1M | $29.1M | ||
| Q1 24 | $80.5M | $26.0M |
| Q4 25 | $29.2M | $-47.5M | ||
| Q3 25 | $50.8M | $-52.9M | ||
| Q2 25 | $20.7M | $-46.6M | ||
| Q1 25 | $26.0M | $-49.5M | ||
| Q4 24 | $40.7M | $-43.3M | ||
| Q3 24 | $-91.5M | $-43.6M | ||
| Q2 24 | $35.8M | $-32.3M | ||
| Q1 24 | $-104.5M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 39.7% | -82.2% | ||
| Q3 25 | 82.8% | -102.6% | ||
| Q2 25 | 29.4% | -93.4% | ||
| Q1 25 | 39.7% | -143.7% | ||
| Q4 24 | 57.9% | -98.6% | ||
| Q3 24 | -127.8% | -132.0% | ||
| Q2 24 | 44.2% | -139.2% | ||
| Q1 24 | -129.6% | -538.7% |
| Q4 25 | 39.9% | -83.0% | ||
| Q3 25 | 82.4% | -103.1% | ||
| Q2 25 | 29.3% | -96.1% | ||
| Q1 25 | 39.5% | -151.4% | ||
| Q4 24 | 57.7% | -103.6% | ||
| Q3 24 | -127.9% | -131.2% | ||
| Q2 24 | 44.1% | -110.9% | ||
| Q1 24 | -129.8% | -544.4% |
| Q4 25 | $0.19 | $-0.73 | ||
| Q3 25 | $0.34 | $-0.82 | ||
| Q2 25 | $0.12 | $-0.75 | ||
| Q1 25 | $0.16 | $-0.81 | ||
| Q4 24 | $0.25 | $-0.71 | ||
| Q3 24 | $-0.69 | $-0.73 | ||
| Q2 24 | $0.23 | $-0.55 | ||
| Q1 24 | $-0.76 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $139.8M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $139.1M |
| Total Assets | $9.9B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $139.8M | $388.9M | ||
| Q3 25 | $245.9M | $416.1M | ||
| Q2 25 | $177.6M | $291.0M | ||
| Q1 25 | $166.4M | $314.5M | ||
| Q4 24 | $317.4M | $320.6M | ||
| Q3 24 | $194.3M | $298.4M | ||
| Q2 24 | $174.7M | $319.1M | ||
| Q1 24 | $161.2M | $201.2M |
| Q4 25 | $1.9B | $139.1M | ||
| Q3 25 | $1.9B | $148.8M | ||
| Q2 25 | $1.8B | $-11.9M | ||
| Q1 25 | $1.9B | $18.9M | ||
| Q4 24 | $1.9B | $21.7M | ||
| Q3 24 | $1.9B | $11.2M | ||
| Q2 24 | $2.0B | $39.3M | ||
| Q1 24 | $2.0B | $61.6M |
| Q4 25 | $9.9B | $480.2M | ||
| Q3 25 | $9.5B | $506.9M | ||
| Q2 25 | $9.8B | $372.7M | ||
| Q1 25 | $8.8B | $386.7M | ||
| Q4 24 | $8.4B | $392.3M | ||
| Q3 24 | $9.1B | $363.6M | ||
| Q2 24 | $9.3B | $381.8M | ||
| Q1 24 | $9.2B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.5M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 4.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.5M | $-25.4M | ||
| Q3 25 | $31.7M | $-26.6M | ||
| Q2 25 | $63.2M | $-23.3M | ||
| Q1 25 | $39.3M | $-40.4M | ||
| Q4 24 | $200.3M | $-18.8M | ||
| Q3 24 | $47.2M | $-25.2M | ||
| Q2 24 | $50.2M | $-29.1M | ||
| Q1 24 | $52.8M | $-40.7M |
| Q4 25 | 4.88× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 3.05× | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | 4.93× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
